HIV DNA vaccine - FIT Biotech/IAVI

Drug Profile

HIV DNA vaccine - FIT Biotech/IAVI

Alternative Names: DNA-GTU vaccine; FIT-06; GTU MultiHIV; GTU-multi-HIV B clade DNA vaccine; GTU®-multiHIV B Clade Vaccine

Latest Information Update: 02 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator FIT Biotech
  • Developer FIT Biotech; Imperial College of Science, Technology and Medicine
  • Class AIDS vaccines; DNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II HIV infections

Most Recent Events

  • 06 Sep 2018 FIT Biotech, European HIV Vaccine Alliance Consortium, Imperial College London and Inserm-ANRS plan the phase I/II EHVAT01 trial for HIV infections in United Kingdom, France, Switzerland and Europe (IM, Injection) in the fourth quarter of 2018 , (NCT02972450)
  • 26 Jun 2018 UK MHRA approves IND application for phase I/II trial in HIV infections
  • 12 Jun 2018 Swiss medic approves IND application for phase I/II trial in HIV infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top